会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • OBJECT-ORIENTED VIDEO SYSTEM
    • 面向对象的视频系统
    • WO1998011730A1
    • 1998-03-19
    • PCT/GB1997002496
    • 1997-09-12
    • BRITISH TECHNOLOGY GROUP PLCMONRO, Donald, MartinNICHOLLS, Jeremy, Andrew
    • BRITISH TECHNOLOGY GROUP PLC
    • H04N07/36
    • H04N19/88H04N19/132H04N19/152H04N19/176H04N19/18H04N19/23H04N19/37H04N19/50H04N19/503H04N19/507H04N19/59H04N19/96H04N19/99
    • An object-oriented video system is implemented as a two layer object model in a software-only video compressor. Quadtree decomposition on an error metric between the input and transmitted images directs the coder towards a foreground layer of active image fragments. A rate buffering system limits the bandwidth by transmitting only the foreground blocks which most improve the image and are above some error threshold. A high fidelity background layer is identified and communicated to the decoder, which can be used to redraw background fragments as foreground objects move across them. Blocks can be coded by various methods, such as fractal transforms or truncated DCTs. The system can be implemented in RISC processors without the need for dedicated hardware. It is suitable for low bit rate applications with slowly varying backgrounds, such as personal video communications over packet networks, or closed circuit TV surveillance.
    • 面向对象的视频系统在仅软件视频压缩器中实现为双层对象模型。 输入和传输图像之间的误差度量的四叉树分解将编码器指向活动图像片段的前景层。 速率缓冲系统通过仅发送最大程度提高图像并高于某个误差阈值的前景块来限制带宽。 识别高保真背景层并将其传达到解码器,该解码器可用于当前景对象在其上移动时用于重绘背景片段。 块可以通过各种方法进行编码,例如分形变换或截断DCT。 该系统可以在RISC处理器中实现,而无需专用硬件。 它适用于具有缓慢变化背景的低比特率应用,例如通过分组网络的个人视频通信或闭路电视监视。
    • 2. 发明申请
    • ANTI-CANCER COMPOUNDS
    • 抗癌化合物
    • WO1992016512A1
    • 1992-10-01
    • PCT/GB1992000476
    • 1992-03-18
    • BRITISH TECHNOLOGY GROUP PLCIMPERIAL CHEMICAL INDUSTRIES PLCBISSET, Graham, Michael, FraserJACKMAN, Ann, LesleyJODRELL, Duncan, Ian
    • BRITISH TECHNOLOGY GROUP PLCIMPERIAL CHEMICAL INDUSTRIES PLC
    • C07D239/95
    • C07D239/95C07D239/90
    • Quinazolines of formula (I), wherein R1 is hydrogen or amino, or R1 is alkyl, alkoxy or alkylthio each of up to 6 carbon atoms; or R1 is aryl or aryloxy each of up to 10 carbon atoms; or R1 is halogeno, hydroxy or mercapto; or R1 is alkyl of up to 3 carbon atoms which bears one or more substituents selected from halogeno, hydroxy and alkanoylamino each of up to 6 carbon atoms; or R1 is alkoxy of up to 3 carbon atoms which bears one or more substituents selected from hydroxy and alkoxy of up to 6 carbon atoms; wherein R2 is hydrogen or alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, mercaptoalkyl, alkylthioalkyl, halogenoalkyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkanoylalkyl, carboxyalkyl, carbamoylalkyl or alkanoyl each of up to 6 carbon atoms; wherein Ar is phenylene or heterocyclene which is unsubstituted or which bears one or more substituents selected from halogeno, cyano, nitro, hydroxy, amino and carbamoyl and alkyl, alkoxy, halogenoalkyl, alkanoylamino, alkylthio and alkoxycarbonyl each of up tp 6 carbon atoms;R3 is the residue of a dipeptide in which the first, N-terminal amino acid residue thereof attached to the carbonyl group of COR3 is an L- or D-amino acid residue -NHCH(CO¿2?H)-A-CO- in which A is an alkylene group of up to 6 carbon atoms and the second amino acid residue is of an α-amino acid which has the D-configuration at its asymmetric α-carbon atom; wherein R?4¿ is hydrogen or alkyl of up to 4 carbon atoms; wherein R5 is hydrogen or alkyl of up to 4 carbon atoms; and wherein each of R?6, R7 and R8¿ is hydrogen or alkyl or alkoxy each of up to 4 carbon atoms; or is halogeno; or a pharmaceutically-acceptable salt, ester or amide thereof are of therapeutic value, particularly in the treatment of cancer.